Metabolism - Clinical and Experimental
Volume 55, Issue 7 , Pages 980-988 , July 2006

Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system

  • Blanca Ripollés Piquer

      Affiliations

    • Laboratoire de Biochimie Générale et Appliquée, UFR de Pharmacie, Université de Nantes, 44035 Nantes, France
    • Laboratoire d'Etude sur le Polymorphisme de L'ADN, EA3823, Faculté de Médecine et de Pharmacie, Université de Nantes, 44035 Nantes, France
    • ,
  • Hassan Nazih

      Affiliations

    • Laboratoire de Biochimie Générale et Appliquée, UFR de Pharmacie, Université de Nantes, 44035 Nantes, France
    • Laboratoire d'Etude sur le Polymorphisme de L'ADN, EA3823, Faculté de Médecine et de Pharmacie, Université de Nantes, 44035 Nantes, France
    • ,
  • Arnaud Bourreille

      Affiliations

    • Service Gastroentérologie, Pôle Digestif, Faculté de Médecine et CHU, Université de Nantes, 44093 Nantes, France
    • ,
  • Jean Pierre Segain

      Affiliations

    • Laboratoire des Fonctions Digestives et de Nutrition Humaine, INRA, 44316 Nantes, France
    • ,
  • Jean Michel Huvelin

      Affiliations

    • Laboratoire de Biochimie Générale et Appliquée, UFR de Pharmacie, Université de Nantes, 44035 Nantes, France
    • Laboratoire d'Etude sur le Polymorphisme de L'ADN, EA3823, Faculté de Médecine et de Pharmacie, Université de Nantes, 44035 Nantes, France
    • ,
  • Jean-Paul Galmiche

      Affiliations

    • Service Gastroentérologie, Pôle Digestif, Faculté de Médecine et CHU, Université de Nantes, 44093 Nantes, France
    • ,
  • Jean-Marie Bard

      Affiliations

    • Laboratoire de Biochimie Générale et Appliquée, UFR de Pharmacie, Université de Nantes, 44035 Nantes, France
    • Laboratoire d'Etude sur le Polymorphisme de L'ADN, EA3823, Faculté de Médecine et de Pharmacie, Université de Nantes, 44035 Nantes, France
    • Corresponding Author InformationCorresponding author. UFR des Sciences Pharmaceutiques, Laboratoire de Biochimie Générale et Biochimie Appliquée, 1, Rue Gaston Veil, 44035 Nantes, France. Tel.: +33 2 40 41 28 69; fax: +33 2 40 41 28 68.

Received 12 July 2005 ,Accepted 2 March 2006.

References 

  1. Hardardóttir I, Grünfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol. 1994;5:207–215
  2. Levy E, Rizwan Y, Thibault L, Lepage G, Brunet S, Bouthillier L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr. 2000;71:807–815
  3. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab. 1993;76:1423–1427
  4. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J. 1998;19(Suppl A):A24–A30
  5. Sammalkorpi K, Valtonen V, Kerttula Y, Nikkila E, Taskinen MR. Changes in serum lipoprotein pattern induced by acute infections. Metabolism. 1988;37:859–865
  6. Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis. 1999;144:285–301
  7. Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 1993;102:131–146
  8. Ettinger WH, Miller LD, Albers JJ, Smith TK, Parks JS. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys. J Lipid Res. 1990;31:1099–1107
  9. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439–444
  10. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29–32
  11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  12. Ferrer F, Bigot-Corbel E, N'Guyen P, Krempf M, Bard JM. Quantitative measurement of lipoprotein particles containing both apolipoprotein AIV and apolipoprotein B in human plasma by a noncompetitive ELISA. Clin Chem. 2002;48(6 Pt 1):884–890
  13. de la Llera Moya M, Atger V, Paul JL, Fournier N, Moatti N, Giral P, et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb. 1994;14:1056–1065
  14. Asztalos BF, Sloop CH, Wong L, Roheim PS. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I–containing subpopulations. Biochim Biophys Acta. 1993;1169:291–300
  15. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease—baseline findings of the PAIS project. Atherosclerosis. 2001;156:451–456
  16. Delanghe JR, Langlois MR, De Bacquer D, Mak R, Capel P, Van Renterghem L, et al. Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. Atherosclerosis. 2002;160:471–476
  17. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–432
  18. Hoppin AG, Kaplan LM, Zurakowski D, Leichtner AM, Bousvaros A. Serum leptin in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998;26:500–505
  19. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908–913
  20. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714–1719
  21. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone–releasing acylated peptide from stomach. Nature. 1999;402:656–660
  22. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12:962–971
  23. Hoffman JS, Benditt EP. Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance. J Clin Invest. 1983;71:926–934
  24. Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res. 1995;36:1058–1065
  25. Hudgins LC, Parker TS, Levine DM, Gordon BR, Saal SD, Jiang XC, et al. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J Lipid Res. 2003;44:1489–1498
  26. Gouni I, Oka K, Etienne J, Chan L. Endotoxin-induced hypertriglyceridemia is mediated by suppression of lipoprotein lipase at a post-transcriptional level. J Lipid Res. 1993;34:139–146
  27. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985;75:384–390
  28. Krimbou L, Tremblay M, Davignon J, Cohn JS. Characterization of human plasma apolipoprotein E–containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE. J Lipid Res. 1997;38:35–48
  29. Yamashita S, Sprecher DL, Sakai N, Matsuzawa Y, Tarui S, Hui DY. Accumulation of apolipoprotein E–rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest. 1990;86:688–695
  30. DeLamatre JG, Sarphie TG, Archibold RC, Hornick CA. Metabolism of apoE-free high density lipoproteins in rat hepatome cells: evidence for a retroendocytic pathway. J Lipid Res. 1990;31:191–202
  31. Friedman G, Wernette-Hammond ME, Hui DY, Mahley RW, Innerarity TL. Characterization of lipoprotein receptors on rat Fu5AH hepatome cells. J Lipid Res. 1987;28:1482–1494
  32. Davit-Spraul A, Atger V, Pourci ML, Hadchouel M, Legrand A, Moatti N. Cholesterol efflux from Fu5AH cells to the serum of patients with Alagille syndrome. Importance of the hdl-phospholipids/free cholesterol ratio and of the hdl size distribution. J Lipid Res. 1999;40:328–335
  33. Karlin JB, Johnson WJ, Benedict CR, Chacko GK, Phillips MC, Rothblat GH. Cholesterol flux between cells and high density lipoprotein. Lack of relationship to specific binding of the lipoprotein to the cell surface. J Biol Chem. 1987;262:12557–12564
  34. Rothblat GH, Bamberger M, Phillips MC. Reverse cholesterol transport. Methods Enzymol. 1986;129:628–644
  35. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta–migrating high-density lipoprotein. Biochemistry. 1988;27:25–29
  36. von Eckardstein A, Huang Y, Wu S, Sarmadi AS, Schwarz S, Steinmetz A, et al. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. Arterioscler Thromb Vasc Biol. 1995;15:1755–1763
  37. Nazih H, Nazih-Sanderson F, Krempf M, Huvelin JM, Mercier S, Bard JM. Butyrate stimulates ApoA-IV–containing lipoprotein secretion in differentiated Caco-2 cells: role in cholesterol efflux. J Cell Biochem. 2001;83:230–238
  38. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:R25–R31
  39. Marguet D, Luciani MF, Moynault A, Williamson P, Chimini G. Engulfment of apoptotic cells involves the redistribution of membrane phosphatidylserine on phagocyte and prey. Nat Cell Biol. 1999;1:454–456

PII: S0026-0495(06)00104-1

doi: 10.1016/j.metabol.2006.03.006

Metabolism - Clinical and Experimental
Volume 55, Issue 7 , Pages 980-988 , July 2006

Article Tools

* Image Usage & Resolution